Stem cell therapies for the treatment of radiation-induced normal tissue side effects

Marc Benderitter, Fabio Caviggioli, Alain Chapel, Robert P. Coppes, Chandan Guha, Marco Klinger, Olivier Malard, Fiona Stewart, Radia Tamarat, Peter Van Luijk, Charles L. Limoli

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Significance: Targeted irradiation is an effective cancer therapy but damage inflicted to normal tissues surrounding the tumor may cause severe complications. While certain pharmacologic strategies can temper the adverse effects of irradiation, stem cell therapies provide unique opportunities for restoring functionality to the irradiated tissue bed. Recent Advances: Preclinical studies presented in this review provide encouraging proof of concept regarding the therapeutic potential of stem cells for treating the adverse side effects associated with radiotherapy in different organs. Early-stage clinical data for radiation-induced lung, bone, and skin complications are promising and highlight the importance of selecting the appropriate stem cell type to stimulate tissue regeneration. Critical Issues: While therapeutic efficacy has been demonstrated in a variety of animal models and human trials, a range of additional concerns regarding stem cell transplantation for ameliorating radiation-induced normal tissue sequelae remain. Safety issues regarding teratoma formation, disease progression, and genomic stability along with technical issues impacting disease targeting, immunorejection, and clinical scale-up are factors bearing on the eventual translation of stem cell therapies into routine clinical practice. Future Directions: Follow-up studies will need to identify the best possible stem cell types for the treatment of early and late radiation-induced normal tissue injury. Additional work should seek to optimize cellular dosing regimes, identify the best routes of administration, elucidate optimal transplantation windows for introducing cells into more receptive host tissues, and improve immune tolerance for longer-term engrafted cell survival into the irradiated microenvironment. Antioxid. Redox Signal. 21: 338-355.

Original languageEnglish (US)
Pages (from-to)338-355
Number of pages18
JournalAntioxidants and Redox Signaling
Volume21
Issue number2
DOIs
StatePublished - Jul 10 2014

Fingerprint

Cell- and Tissue-Based Therapy
Stem cells
Stem Cells
Radiation
Tissue
Bearings (structural)
Therapeutics
Irradiation
Tissue regeneration
Immune Tolerance
Genomic Instability
Teratoma
Radiotherapy
Stem Cell Transplantation
Oxidation-Reduction
Disease Progression
Tumors
Regeneration
Neoplasms
Cell Survival

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology
  • Physiology
  • Clinical Biochemistry
  • Medicine(all)

Cite this

Benderitter, M., Caviggioli, F., Chapel, A., Coppes, R. P., Guha, C., Klinger, M., ... Limoli, C. L. (2014). Stem cell therapies for the treatment of radiation-induced normal tissue side effects. Antioxidants and Redox Signaling, 21(2), 338-355. https://doi.org/10.1089/ars.2013.5652

Stem cell therapies for the treatment of radiation-induced normal tissue side effects. / Benderitter, Marc; Caviggioli, Fabio; Chapel, Alain; Coppes, Robert P.; Guha, Chandan; Klinger, Marco; Malard, Olivier; Stewart, Fiona; Tamarat, Radia; Luijk, Peter Van; Limoli, Charles L.

In: Antioxidants and Redox Signaling, Vol. 21, No. 2, 10.07.2014, p. 338-355.

Research output: Contribution to journalArticle

Benderitter, M, Caviggioli, F, Chapel, A, Coppes, RP, Guha, C, Klinger, M, Malard, O, Stewart, F, Tamarat, R, Luijk, PV & Limoli, CL 2014, 'Stem cell therapies for the treatment of radiation-induced normal tissue side effects', Antioxidants and Redox Signaling, vol. 21, no. 2, pp. 338-355. https://doi.org/10.1089/ars.2013.5652
Benderitter, Marc ; Caviggioli, Fabio ; Chapel, Alain ; Coppes, Robert P. ; Guha, Chandan ; Klinger, Marco ; Malard, Olivier ; Stewart, Fiona ; Tamarat, Radia ; Luijk, Peter Van ; Limoli, Charles L. / Stem cell therapies for the treatment of radiation-induced normal tissue side effects. In: Antioxidants and Redox Signaling. 2014 ; Vol. 21, No. 2. pp. 338-355.
@article{58685115bccf40f5aefa41de8da33122,
title = "Stem cell therapies for the treatment of radiation-induced normal tissue side effects",
abstract = "Significance: Targeted irradiation is an effective cancer therapy but damage inflicted to normal tissues surrounding the tumor may cause severe complications. While certain pharmacologic strategies can temper the adverse effects of irradiation, stem cell therapies provide unique opportunities for restoring functionality to the irradiated tissue bed. Recent Advances: Preclinical studies presented in this review provide encouraging proof of concept regarding the therapeutic potential of stem cells for treating the adverse side effects associated with radiotherapy in different organs. Early-stage clinical data for radiation-induced lung, bone, and skin complications are promising and highlight the importance of selecting the appropriate stem cell type to stimulate tissue regeneration. Critical Issues: While therapeutic efficacy has been demonstrated in a variety of animal models and human trials, a range of additional concerns regarding stem cell transplantation for ameliorating radiation-induced normal tissue sequelae remain. Safety issues regarding teratoma formation, disease progression, and genomic stability along with technical issues impacting disease targeting, immunorejection, and clinical scale-up are factors bearing on the eventual translation of stem cell therapies into routine clinical practice. Future Directions: Follow-up studies will need to identify the best possible stem cell types for the treatment of early and late radiation-induced normal tissue injury. Additional work should seek to optimize cellular dosing regimes, identify the best routes of administration, elucidate optimal transplantation windows for introducing cells into more receptive host tissues, and improve immune tolerance for longer-term engrafted cell survival into the irradiated microenvironment. Antioxid. Redox Signal. 21: 338-355.",
author = "Marc Benderitter and Fabio Caviggioli and Alain Chapel and Coppes, {Robert P.} and Chandan Guha and Marco Klinger and Olivier Malard and Fiona Stewart and Radia Tamarat and Luijk, {Peter Van} and Limoli, {Charles L.}",
year = "2014",
month = "7",
day = "10",
doi = "10.1089/ars.2013.5652",
language = "English (US)",
volume = "21",
pages = "338--355",
journal = "Antioxidants and Redox Signaling",
issn = "1523-0864",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Stem cell therapies for the treatment of radiation-induced normal tissue side effects

AU - Benderitter, Marc

AU - Caviggioli, Fabio

AU - Chapel, Alain

AU - Coppes, Robert P.

AU - Guha, Chandan

AU - Klinger, Marco

AU - Malard, Olivier

AU - Stewart, Fiona

AU - Tamarat, Radia

AU - Luijk, Peter Van

AU - Limoli, Charles L.

PY - 2014/7/10

Y1 - 2014/7/10

N2 - Significance: Targeted irradiation is an effective cancer therapy but damage inflicted to normal tissues surrounding the tumor may cause severe complications. While certain pharmacologic strategies can temper the adverse effects of irradiation, stem cell therapies provide unique opportunities for restoring functionality to the irradiated tissue bed. Recent Advances: Preclinical studies presented in this review provide encouraging proof of concept regarding the therapeutic potential of stem cells for treating the adverse side effects associated with radiotherapy in different organs. Early-stage clinical data for radiation-induced lung, bone, and skin complications are promising and highlight the importance of selecting the appropriate stem cell type to stimulate tissue regeneration. Critical Issues: While therapeutic efficacy has been demonstrated in a variety of animal models and human trials, a range of additional concerns regarding stem cell transplantation for ameliorating radiation-induced normal tissue sequelae remain. Safety issues regarding teratoma formation, disease progression, and genomic stability along with technical issues impacting disease targeting, immunorejection, and clinical scale-up are factors bearing on the eventual translation of stem cell therapies into routine clinical practice. Future Directions: Follow-up studies will need to identify the best possible stem cell types for the treatment of early and late radiation-induced normal tissue injury. Additional work should seek to optimize cellular dosing regimes, identify the best routes of administration, elucidate optimal transplantation windows for introducing cells into more receptive host tissues, and improve immune tolerance for longer-term engrafted cell survival into the irradiated microenvironment. Antioxid. Redox Signal. 21: 338-355.

AB - Significance: Targeted irradiation is an effective cancer therapy but damage inflicted to normal tissues surrounding the tumor may cause severe complications. While certain pharmacologic strategies can temper the adverse effects of irradiation, stem cell therapies provide unique opportunities for restoring functionality to the irradiated tissue bed. Recent Advances: Preclinical studies presented in this review provide encouraging proof of concept regarding the therapeutic potential of stem cells for treating the adverse side effects associated with radiotherapy in different organs. Early-stage clinical data for radiation-induced lung, bone, and skin complications are promising and highlight the importance of selecting the appropriate stem cell type to stimulate tissue regeneration. Critical Issues: While therapeutic efficacy has been demonstrated in a variety of animal models and human trials, a range of additional concerns regarding stem cell transplantation for ameliorating radiation-induced normal tissue sequelae remain. Safety issues regarding teratoma formation, disease progression, and genomic stability along with technical issues impacting disease targeting, immunorejection, and clinical scale-up are factors bearing on the eventual translation of stem cell therapies into routine clinical practice. Future Directions: Follow-up studies will need to identify the best possible stem cell types for the treatment of early and late radiation-induced normal tissue injury. Additional work should seek to optimize cellular dosing regimes, identify the best routes of administration, elucidate optimal transplantation windows for introducing cells into more receptive host tissues, and improve immune tolerance for longer-term engrafted cell survival into the irradiated microenvironment. Antioxid. Redox Signal. 21: 338-355.

UR - http://www.scopus.com/inward/record.url?scp=84902485527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902485527&partnerID=8YFLogxK

U2 - 10.1089/ars.2013.5652

DO - 10.1089/ars.2013.5652

M3 - Article

VL - 21

SP - 338

EP - 355

JO - Antioxidants and Redox Signaling

JF - Antioxidants and Redox Signaling

SN - 1523-0864

IS - 2

ER -